Navigation Links
Onyx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Date:9/16/2010

EMERYVILLE, Calif., Sept. 16 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the UBS Global Life Sciences Conference on Wednesday, September 22, 2010 at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time).

Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available within 24 hours of the completion of the presentation through October 6, 2010.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-phar
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 ... titled "Monochloroacetic Acid (MCA) Market for Cellulosics, Agrochemicals, Surfactants, ... Analysis, Size, Share, Growth, Trends and Forecast 2014 - ... USD 817.1 million in 2013 and is anticipated to ... CAGR of 3.6% during the forecast period from 2014 ...
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... is available in its catalogue: Global ... http://www.reportlinker.com/p01375204/Global-Coatings-for-Medical-Devices-Industry.html This report ... Devices in US$ Million by the following Product ... Nanotechnology Coatings. The report provides separate comprehensive analytics ...
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 ... available in its catalogue: Global Feminine Hygiene ... This report analyzes the worldwide markets for Feminine ... Segments: Sanitary Pads/Towels, Tampons, Panty liners, and Others. The ... Canada , Japan , ...
Breaking Medicine Technology:Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13
(Date:8/21/2014)... The Rottenstein Law Group LLP, a national ... experience advocating for plaintiffs with claims of harm stemming ... the launch of its new website, http://www.wehelpwomen.com , ... have been harmed by prescription drugs or medical devices. ... adverse side effects suffered by women allegedly caused by ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Sometimes you have to ... In his new book “From Zero to a Hundred: Finding My ... shares his story of surviving a broken family, a childhood of ... affirmation of who you were created to be,” Roy said. “I ... is why I know my purpose today of helping others overcome ...
(Date:8/21/2014)... 21, 2014 Teen substance abuse is long ... FL. The rising numbers of young adults falling victim to ... make a difference in the community, the new Troubled Teens ... for teens seeking to overcome something like teenage alcohol ... their teens find the best teen recovery facility to focus ...
(Date:8/21/2014)... Albuquerque, NM (PRWEB) August 21, 2014 ... created by the Centers for Disease Control and ... facilities in assessing their compliance with the immunization ... policies and the CDC's General Recommendations on Immunizations. ... one of the many procedures in place to ...
(Date:8/21/2014)... 21, 2014 Drake University’s Phi Gamma ... to support ovarian cancer research, according to Billy Cundiff, ... also the kicker for the Cleveland Browns, says the ... matched by Colleen’s Dream Foundation and will fund research ... Professor in the Division of Gynecologic Oncology at the ...
Breaking Medicine News(10 mins):Health News:Rottenstein Law Group LLP Announces Launch of WeHelpWomen.com 2Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2Health News:New Helpline Provides Hope for Troubled Teens in Boca Raton 2Health News:ACC Health Raises the Bar Again by Completing the CQIIP Certification Program 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 2Health News:Drake University’s Phi Gamma Delta (FIJI) and Colleen’s Dream Foundation Donate $10,000 to the University of Iowa’s Holden Cancer Center to Fight Ovarian Cancer 3
... 15 Heska Corporation,(Nasdaq: HSKA ) announces the following Webcast:, ... Heska Corporation Invites You to Join Its Fourth Quarter and ... on the Web, When: Tuesday, February 26, 2008 ... on the Q4 and Year-End 2007 Earnings ...
... MD (February 15, 2008) -- Aiming to promote the ... health and safety of the millions of people who ... United States, the American Association of Physicists in Medicine ... this month recommending standardized ways of reporting doses and ...
... Spheris, a leading global,provider of clinical documentation technology ... to its board of directors., Tsai is ... Warburg,Pincus & Co., one of the world,s largest ... Partners, L.P. hold the,majority ownership of Spheris., ...
... Danish researchers find reducing air particulates for just 2 ... (HealthDay News) -- A breath of filtered indoor air ... , Using high efficiency particle air (HEPA) filters for ... cardiovascular health in healthy, nonsmoking elderly individuals, according to ...
... Association Requests AAP Instead Focus on Removing,Unnecessary Toxins ... Autism, CHICAGO, Feb. 15 The American ... campaign to counter,recent negative publicity surrounding toxins in ... as "part of our ongoing,response to media stories ...
... Feb. 15 /PRNewswire-FirstCall/ - The Westaim Corporation,announced today that for ... of $58.0 million, or 62 cents per share, on revenues ... or 54 cents per share, on,revenues of $27.6 million in ... the Company posted a net loss of $26.8 million, or ...
Cached Medicine News:Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2007 Earnings Conference Call Webcast 2Health News:CT radiation dose report released by American Association of Physicists in Medicine 2Health News:CT radiation dose report released by American Association of Physicists in Medicine 3Health News:Spheris Elects New Board Member 2Health News:HEPA Filters May Improve Cardiovascular Health 2Health News:AAP Initiates Public Relations Effort to Counter Bad Vaccine Publicity 2Health News:Westaim announces 2007 year-end results 2Health News:Westaim announces 2007 year-end results 3Health News:Westaim announces 2007 year-end results 4Health News:Westaim announces 2007 year-end results 5Health News:Westaim announces 2007 year-end results 6Health News:Westaim announces 2007 year-end results 7Health News:Westaim announces 2007 year-end results 8Health News:Westaim announces 2007 year-end results 9Health News:Westaim announces 2007 year-end results 10Health News:Westaim announces 2007 year-end results 11Health News:Westaim announces 2007 year-end results 12
...
A hallmark design that combines the Performance Knee's excellent features and clinical history with Biomet's proven tibial designs. Addresses patient-specific needs by offering various levels of cons...
The AGC Revision Knee, extends the AGC Family to include implants for severe primary knees or revision. Provides rotational freedom of +/- 2 and varus/valgus freedom of +/- 1.5....
The Advance stemmed medial-pivot knee is a revision knee that provides unique and competitive features....
Medicine Products: